Increased numbers of T helper 17 cells and the correlation with clinicopathological characteristics in multiple myeloma

Journal of International Medical Research

Volumn 40, Issue 2, 2012, Pages 556-564

  Shen, C J ^a   Yuan, Z H ^a   Liu, Y X ^a   Hu, G Y ^a  

^a ZHUZHOU CENTRAL HOSPITAL   (China)

Author keywords

Interleukin 17; Multiple myeloma; T helper 17 cells

Indexed keywords

CREATININE; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 6; LACTATE DEHYDROGENASE;

ADULT; AGED; ARTICLE; CANCER STAGING; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MULTIPLE MYELOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN BLOOD LEVEL; TH17 CELL;

EID: 84860476030     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001204000217     Document Type: Article

References (29)

1. Kyle RA, Rajkumar SV: Multiple myeloma. N Engl J Med 2004; 351: 1860-1873.
2. Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
3. de Carvalho F, Colleoni GW, Almeida MS, et al: TGFβR2 aberrant methylation is a potential prognostic marker and therapeutic target in multiple myeloma. Int J Cancer 2009; 125: 1985-1991.
4. + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005; 6: 1123-1132.
5. Park H, Li Z, Yang XO, et al: A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005; 6: 1133-1141.
6. Ji Y, Zhang W: Th17 cells: positive or negative role in tumor? Cancer Immunol Immunother 2010; 59: 979-987.
7. Littman DR, Rudensky AY: Th17 and regulatory T cells in mediating and restraining inflammation. Cell 2010; 140: 845-858.
8. Sallusto F, Lanzavecchia A: Human Th17 cells in infection and autoimmunity. Microbes Infect 2009; 11: 620-624.
9. Wilke CM, Kryczek I, Wei S, et al: Th17 cells in cancer: help or hindrance? Carcinogenesis 2011; 32: 643-649.
10. International Myeloma Working Group: Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749-757.
11. Greipp PR, San Miguel J, Durie BG, et al: International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420.
12. Durie BGM, Harousseau J-L, Miguel JS, et al: International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473.
13. Bladé J, Cibeira MT, Fernández de Larrea C, et al: Multiple myeloma. Ann Oncol 2010; 21(suppl 7): vii 313-vii 319.
14. Orlowski RZ: Bortezomib and its role in the management of patients with multiple myeloma. Expert Rev Anticancer Ther 2004; 4: 171-179.
15. Whiteside TL: Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression. Expert Opin Biol Ther 2010; 10: 1019-1035.
16. Kryczek I, Banerjee M, Cheng P, et al: Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 2009; 114: 1141-1149.
17. Sfanos KS, Bruno TC, Maris CH, et al: Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res 2008; 14: 3254-3261.
18. + T cells in malignant pleural effusion. J Immunol 2010; 185: 6348-6354.
19. + T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients. Int J Cancer 2009; 125: 1372-1379.
20. Dhodapkar KM, Barbuto S, Matthews P, et al: Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma. Blood 2008; 112: 2878-2885.
21. Prabhala RH, Pelluru D, Fulciniti M, et al: Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood 2010; 115: 5385-5392.
22. Noonan K, Marchionni L, Anderson J, et al: A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma. Blood 2010; 116: 3554-3563.
23. Koskela K, Pelliniemi TT, Rajamäki A, et al: Serum oncostatin M in multiple myeloma: impact on disease severity and prognosis. Eur J Haematol 2000; 65: 52-56.
24. Numasaki M, Fukushi J, Ono M, et al: Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003; 101: 2620-2627.
25. Chen X, Wan J, Liu J, et al: Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. Lung Cancer 2010; 69: 348-354.
26. Zhang JP, Yan J, Xu J, et al: Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol 2009; 50: 980-989.
27. Zou W, Restifo NP: TH17 cells in tumour immunity and immunotherapy. Nat Rev Immunol 2010; 10: 248-256.
28. Wu C, Wang S, Wang F, et al: Increased frequencies of T helper type 17 cells in the peripheral blood of patients with acute myeloid leukaemia. Clin Exp Immunol 2009; 158: 199-204.
29. Kyrtsonis MC, Maltezas D, Tzenou T, et al: Staging systems and prognostic factors as a guide to therapeutic decisions in multiple myeloma. Semin Hematol 2009; 46: 110-117.